Table 2.
Indications of sirolimus therapy
| Variable | N (%) |
|---|---|
| Renal dysfunctiona | 318 (55.2) |
| HCC | |
| Prophylaxis | 93 (16.1) |
| Recurrence | 21 (3.6) |
| Non-hepatic tumors | 18 (3.1) |
| Biopsy proved acute/chronic rejection | 84 (14.6) |
| Neurotoxicity | 5 (0.9) |
| Other side effects from immunosuppressants | 37 (6.4) |
aDefined by physician’s criteria or eGFR <60 mL/min/1.73 m2 without other reasons for SRL use